Page 5 - Pharma Sector

Indian pharma industry likely to grow to $130 bn by 2030, says IPA

The trade shows are jointly organised by Indian Pharma Machinery Manufacturers Association (IPMMA), Indian Analytical Instruments Association (IAIA) and Messe Muenchen

Core brands, new launches to help Abbott India stock outperform: Analysts

Analysts expect double-digit growth for pharma major even if Q1 disappointed

National List of Essential Medicines: All that you need to know about it

The Ministry of Health and Family Welfare released the first NLEM in 1996. It contained 279 medicines. The list was subsequently revised in 2003 and had 354 medicines

Largest Ibuprofen API maker eyes double revenue in next four years

As part of de-risking their business, they have started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio

Freebies to doctors: Why has the ethical code not been enforced?

Activists have been alleging nexus between pharma companies and doctors, which was echoed in the Apex Court recently. Why's Uniform Code of Pharmaceutical Marketing Practices not legally binding yet?

The New Drugs Bill: A missed opportunity for reforms in Ayush

The Bill takes regressive steps on the issue of drug safety

Centre proposes anti-dumping duty on China antibiotic drug ofloxacin

No impact on end consumer as prices are regulated

DOLO-650 makers distributed freebies worth Rs 1,000 cr to doctors: FMRAI

The petitioner, while seeking statutory backing to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), said that corruption in pharma marketing practices is yet unregulated in India

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

The Hyderabad-based company claimed that BBV154 is proven to be safe, well-tolerated and immunogenic in the subjects under controlled clinical trials

Top Headlines: FPIs cut stake in BSE firms, pharma eyes $400 bn turnover

The Centre's recent move to impose GST on services rendered by the markets regulator, Securities and Exchange Board of India (Sebi), has rattled FPIs

India pharma sector exports rises 8% to $6.26 billion in first quarter

Indian pharma exports registered a growth of eight per cent during the first quarter of the current financial year to $6.26 billion, as officials hope for a 10 per cent growth by the end of the fiscal

Cipla Q1 revenue may be muted on high base, low Covid drug sales: Analysts

Cipla Q1 results preview: Analysts attribute the likely dull performance due to the high base of last year, and the reduction in revenue contribution from Covid-19 therapies in the recent quarter.

Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts

Sun Pharma Q1FY23 results: Prabhudas Lilladher foresees the company's net profit to rise 27 per cent year-on-year (YoY) to Rs 1,786 crores from Rs 1,445 crores in the year-ago quarter.

Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts

Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.

Rupee at 80: Neutral impact for India's pharma industry, say experts

India's pharma sector exported drugs worth Rs 1.8 trillion in 2021-22, while APIs worth Rs 30,000 crore were imported

Research-linked incentive scheme in works for pharmaceutical industry

15% turnover investment in research could make companies eligible for the scheme

Price is the key growth driver of Indian pharma market, shows AWACS data

Market set to grow by 2.5-5% in calendar 2022. could even hit 5% due to a strong seasonal sales such as anti-infectives, and impact of NLEM drugs price hike

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

The firms had launched generic versions of Boehringer's patent-protected drug Linagliptin, which is marketed under the brand name Trajenta

Alembic Pharma gets USFDA approval to market Pirfenidone tablets

Alembic Pharmaceuticals said it has received approval from the US health regulator to market Pirfenidone tablets used to treat lung disease in the American market.